1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1169KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
2. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 3-3
&NA;,
Preview
|
PDF (1042KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 4-4
&NA;,
Preview
|
PDF (1136KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
4. |
Evaluating costs and outcomes in cardiovascular disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 5-6
Heather Patterson,
Preview
|
PDF (2273KB)
|
|
摘要:
Coronary heart disease is the leading cause of death worldwide, implicated in 7.2 million deaths annually, according to the 1997 World Health Report published by the World Health Organization.1Thus, the treatment of cardiovascular disease imposes a large burden on most countries' healthcare budgets. At the Second Annual International Meeting of the Association for Pharmacoeconomics and Outcomes Research [Philadelphia, US; April 1997], US-based researchers presented data from a number of studies evaluating the costs of treatment, and the resulting patient outcomes, for cardiovascular diseases.
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
5. |
Alteplase cost effective in MI |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1198KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 7-7
&NA;,
Preview
|
PDF (1039KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
7. |
Oncology looks beyond chemotherapy for better responses |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 8-9
Robert Carlson,
Preview
|
PDF (2193KB)
|
|
摘要:
Clinical and research oncologists have had an uneasy feeling for several years that conventional anticancer agents may have reached the limit of their potential. Researchers have predicted that the war against cancer will ultimately be won by immunological weapons. New clues about stimulating the immune system and strong correlations between cancer and newly discovered gene mutations appear to validate this direction of attack. Three phase I trial reports presented at the 33rd Annual Meeting of the American Society of Clinical Oncology (ASCO) [Denver, US; May 1997], described the use of ‘targeted cancer therapy’ using adenoviruses that are either cytotoxic in cells with mutations in thep53tumour suppressor gene or that transport normalp53genes into tumour cells.
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
8. |
Pleconaril shortens disease duration in viral meningitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 9-9
&NA;,
Preview
|
PDF (1038KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1096KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
10. |
Assessing roles for endothelin-receptor antagonists |
|
Inpharma Weekly,
Volume &NA;,
Issue 1092,
1997,
Page 11-12
Gill Higgins,
Preview
|
PDF (2218KB)
|
|
摘要:
Endothelin (ET)-receptor antagonists may be useful for the treatment of heart failure in patients who remain symptomatic while receiving standard therapy, according to findings presented at the 8th European Meeting on Hypertension [Milan, Italy; June 1997]. However, another study has indicated that it may not be appropriate to use these agents for treating hypertension in patients with non-insulin-dependent diabetes melllitus (NIDDM).
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|